Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Drug Metabolite
    (1)
  • NR4A
    (1)
  • Others
    (2)
TargetMol | Tags By ResearchField
  • Others
    (1)
Filter
Search Result
Results for "

bdnf (human)

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    4
    TargetMol | All_Pathways
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Recombinant Protein
    5
    TargetMol | Recombinant_Protein
  • Antibody Products
    5
    TargetMol | Antibody_Products
  • Reference Standards
    1
    TargetMol | Standard_Products
BDNF (human)
TP2069218441-99-7
Member of the neurotrophin growth factor family that binds and activates TrkB and p75 neurotrophin receptors. Enhances the survival, growth and differentiation of neurons. BDNF expression is altered in neurodegenerative disorders such as Parkinson's and A
  • $1,530
35 days
Size
QTY
Nurr1 agonist 12
T206188
Nurr1 agonist 12 (Compound 37) acts as an agonist of the nuclear receptor-related protein 1 (Nurr1), enhancing its transcriptional activity with an EC50 of 0.06 μM. It stimulates human response elements NBRE, NurRE, and DR5 with EC50 values of 0.07 μM, 0.027 μM, and 0.014 μM, respectively. Additionally, Nurr1 agonist 12 induces the expression of neurotrophic genes regulated by Nurr1, such as tyrosine hydroxylase (TH), SOD1/2, BDNF, Sestrin 3, and BIRC5 (Survivin). The compound also demonstrates neuroprotective effects against neurotoxicity caused by Paraquat.
  • Inquiry Price
Inquiry
Size
QTY
Reduced Haloperidol
T3716734104-67-1
Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.
  • $223
35 days
Size
QTY
Reduced Haloperidol in Methanol, Concentration: 1000 µg/mL (Standard)
TMSM-341934104-67-1
Reduced Haloperidol (Standard) is a reference standard for research and analysis in studies involving Reduced Haloperidol. Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.
  • $153
7-10 days
Size
QTY